Bronze
None
| Address | Parc 1 Tower 2 23F, 108, Yeoui-daero, Yeongdeungpo-gu, Seoul 07335 Korea | ||
|---|---|---|---|
| Telephone | +82-2-829-6600 | Fax | None |
| Website | www.bayer.com | None | |
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.
Vitrakvi®(Larotrectinib) is a tumor-agnostic drug exclusively designed to treat NTRK gene fusion positive cancer. It is approved to treat NTRK gene fusion positive cancer in adults as well as in pediatrics(≥ 1 month). It is highly effective with 79% ORR in a pooled analysis of three phase 1/2 clinical trials.
